Perceptive Advisors LLC Arrowhead Pharmaceuticals, Inc. Transaction History

Perceptive Advisors LLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 15, 2021	SELL	$58.38 - $84.96 $18.4 Million - $26.8 Million	-315,141 Closed	0 $0
Q2 2021 Aug 16, 2021	SELL	$62.15 - $90.32 $5.85 Million - $8.51 Million	-94,200 Reduced 23.01%	315,141 $26.1 Million
Q1 2021 May 17, 2021	SELL	$61.35 - $90.47 $40.6 Million - $59.8 Million	-661,473 Reduced 61.77%	409,341 $27.1 Million
Q4 2020 Feb 16, 2021	BUY	$43.82 - $85.37 $46.9 Million - $91.4 Million	1,070,814 New	1,070,814 $82.2 Million
Q1 2020 May 15, 2020	SELL	$20.56 - $63.12 $631,973 - $1.94 Million	-30,738 Closed	0 $0
Q3 2019 Nov 14, 2019	SELL	$26.26 - $34.86 $7.88 Million - $10.5 Million	-300,000 Reduced 90.71%	30,738 $866,000
Q1 2019 May 15, 2019	BUY	$12.05 - $20.18 $370,392 - $620,292	30,738 Added 10.25%	330,738 $6.07 Million
Q4 2018 Feb 14, 2019	SELL	$10.74 - $19.7 $702,879 - $1.29 Million	-65,445 Reduced 17.91%	300,000 $3.58 Million
Q1 2018 May 15, 2018	BUY	$3.72 - $7.64 $1.36 Million - $2.79 Million	365,445 New	365,445 $2.64 Million

295

92.3M

1.33M

549K

Ticker ARWR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 105,849,000
Market Cap $2B
Description
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Perceptive Advisors LLC with notifications on news.